GlassScriptPhysician profile
Allison K Hower
NPI 1801367867
$4,853.25
in general payments reported to CMS, 2019-2025
30 companies · $1,991 in 2025
The $1,991 reported for 2025 was more than what 96% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $391 · 2023: $1,170 · 2024: $1,301 · 2025: $1,991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,461.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,000.60 | 2022-2025 | |
| Novo Nordisk INC | $791.95 | 2022-2025 | Wegovy, Ozempic |
| Otsuka America Pharmaceutical, INC. | $445.25 | 2022-2025 | Rexulti |
| Exact Sciences Corporation | $309.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $247.47 | 2023-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.63 | 2022-2025 | Jardiance |
| Axsome Therapeutics, INC. | $161.29 | 2024-2025 | Auvelity, Symbravo |
| Novartis Pharmaceuticals Corporation | $159.12 | 2022-2025 | |
| Astellas Pharma US INC | $156.52 | 2023-2025 | Veozah |
| Pfizer INC. | $148.79 | 2023-2025 | |
| Lilly USA, LLC | $142.05 | 2022-2025 | Mounjaro, Zepbound |
| Sumitomo Pharma America, INC. | $126.24 | 2025 | Gemtesa |
| Almatica Pharma LLC | $113.98 | 2024-2025 | Loreev Xr, Teriparatide |
| Glaxosmithkline, LLC. | $104.67 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lundbeck LLC | $99.70 | 2023-2025 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $93.16 | 2022-2025 | Seglentis, Zoryve, Livalo |
| Amgen INC. | $84.62 | 2022-2025 | Otezla, Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.60 | 2022-2024 | Caplyta |
| Harmony Biosciences LLC | $64.10 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.00 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $36.04 | 2022 | |
| Janssen Pharmaceuticals, INC | $35.07 | 2025 | Spravato |
| Neurelis, INC. | $31.23 | 2022 | |
| Ironshore Pharmaceuticals INC. | $23.21 | 2023 | Jornay Pm |
| Esperion Therapeutics, INC. | $19.82 | 2024 | Nexletol |
| Idorsia Pharmaceuticals US INC | $17.15 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $15.90 | 2025 | Contrave |
| Neos Therapeutics, LP | $15.25 | 2022 | |
| Hikma Pharmaceuticals USA | $13.95 | 2023 | Ryaltris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Hower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.